A new post-stroke care pathway from Viz.ai and Medtronic is associated with significant benefits, including higher patient and clinician satisfaction.

More than 100 incidents have been reported so far. The FDA is still evaluating this issue, but the agency wanted to raise awareness as quickly as possible.

Last summer more than 40% of 121 hospital executives surveyed said their organization had already realized a decent ROI in generative AI. However, a C-suite slice of nearly the same size said it was too soon to know for sure.